No

Associated Studies:

Division Study Number Title Investigator(s) Release Date
CTN NIDA-CTN-0134 Identifying Regional “Hotspots” and Potential Correlates of Precipitated Withdrawal During Buprenorphine Induction in Fentanyl Users Through Prescriber Survey Responses and Patient Urine Drug Test Results (Buprenorphine-Precipitated Withdrawal Hotspots and Correlates) LaTrice Montgomery, Ph.D., T. John Winhusen, Ph.D.
CTN NIDA-CTN-0083 Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services (Social Media PrEP) Jeffrey D. Klausner, M.D.
CTN NIDA-CTN-0069 Opioid Use Disorder in the Emergency Department (ED-HEALTH) David A. Fiellin, M.D., Gail D'Onofrio, M.D., M.S.
CTN NIDA-CTN-0081 Capturing Opioid Use Disorder Electronically & Patient Reported Outcomes (CODE-PRO) Arjun Krishna Venkatesh, MD, MBA, MHS, Kathryn Hawk, M.D., M.H.S., Richard Andrew Taylor, MD, MHS
CTN NIDA-CTN-0079 Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT) John Rotrosen, M.D., Kathryn Hawk, M.D., M.H.S., Ryan McCormack, M.D.
CTN NIDA-CTN-0064 Assessing Long-term CTN-0049 Outcomes, HCV Prevalence and Progression along the HCV Care Continuum among HIV/HCV Co-infected Substance Users in the U.S. Carlos del Rio, M.D., Carmen Masson, Ph.D., Daniel J. Feaster, Ph.D., David Perlman, M.D., Lisa Metsch, Ph.D.
DTMC NIDA-CSP-1033 Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder Shwe Gyaw, M.D.
CTN NIDA-CTN-0055 Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES) P. Todd Korthuis, MD
CTN NIDA-CTN-0051A2 Treatment-as-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with NIDA CTN-0051 John Rotrosen, M.D.
CTN NIDA-CTN-0067 Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up P. Todd Korthuis, MD
CTN NIDA-CTN-0075 Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder Li-Tzy Wu, ScD., Paolo Mannelli, MD
DTMC NIDA-CPU-0011 Ph1 Marinol Interaction Study - Part 1 Louis Cantilena, Jr., M.D, Ph.D.
CTN NIDA-CTN-0068 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-2) Madhukar H. Trivedi, M.D.
CTN NIDA-CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT) Walter Ling, M.D.
DTMC NIDA-CPU-0010 Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine Louis Cantilena, Jr., M.D, Ph.D.
GRNT NIDA-CENIC-P1S1 Investigating the Impact of Nicotine Using Spectrum Cigarettes (P1S1) - Grant U54-DA031659 Eric C. Donny, Ph.D.
DTMC NIDA-CTO-0011 Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D.
DTMC NIDA-CTO-0012 Phase 2, Double-Blind, Placebo-Controlled Trial Of Tiagabine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
CTN NIDA-CTN-0049 Project HOPE - Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users Lisa Metsch, Ph.D., Carlos del Rio, M.D.
CTN NIDA-CTN-0053 Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment (ACCENT) Kevin M. Gray, MD
DTMC NIDA-MDS-0002 Assessment of Interactions Between Methamphetamine and Aripiprazole Thomas F. Newton, M.D.
DTMC NIDA-CTO-0010 Assessment of Potential Interactions Between Methamphetamine and Bupropion Thomas F. Newton, M.D.
DTMC NIDA-CTO-0008 Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence Richard Rawson, Ph.D.
DTMC NIDA-CSP-1022 Phase 2, Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System (STS) As An Aid For Smoking Cessation Elbert D. Glover, PhD, FASHA, FAAHB, FRIPH
DTMC NIDA-CSP-1021 Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence Liza Gorgon, M.A.
DTMC NIDA-CSP-1019 Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D.
CTN NIDA-CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment John Rotrosen, M.D.
DTMC NIDA-MDS-0003 Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram John D. Roache, Ph.D.
DTMC NIDA-CPU-0008 Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil Reese Jones, M.D.
DTMC NIDA-CTO-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence Steven Shoptaw, Ph.D., Thomas F. Newton, M.D.
DTMC NIDA-CSP-1020 A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal Ann Montgomery, R.N.
CTN NIDA-CTN-0059 The TAPS Tool: Screen and Brief Assessment Tool Validation Study Robert P Schwartz, M.D., Li-Tzy Wu, ScD., Jennifer McNeely, M.D.
CTN NIDA-CTN-0056 Testing and Linkage to HIV Care in China: A Cluster Randomized Trial Zunyou Wu, MD, PhD
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D.
DTMC NIDA-CPU-0006 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine Reese Jones, M.D.
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D.
DTMC NIDA-CTO-0006 Cocaine-Metyrapone Interaction Study Bonita Singal, M.D., T. John Winhusen, Ph.D.
DTMC NIDA-CTO-0005 Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence John D. Roache, Ph.D.
DTMC NIDA-CTO-0004 Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline Thomas F. Newton, M.D.
DTMC NIDA-CTO-0003 Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone Thomas F. Newton, M.D.
DTMC NIDA-CTO-0002 Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine Robert J. Malcolm, M.D., C. Lindsay DeVane, Pharm.D.
CTN NIDA-CTN-0017 HIV and HCV Risk Reduction Interventions in Drug Detoxification and Treatment Settings Robert Booth, Ph.D.
CTN NIDA-CTN-0047 Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED) Michael P. Bogenschutz, M.D., Dennis Donovan, Ph.D.
CTN NIDA-CTN-0018 Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment Donald A. Calsyn, Ph.D.
DTMC NIDA-MDS-0007 Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence Ann Anderson, M.D.
DTMC NIDA-MDS-0004 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence Domenic Ciraulo, M.D.
DTMC NIDA-CTO-0001 Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D.
CTN NIDA-CTN-0052 A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC) T. John Winhusen, Ph.D.
CTN NIDA-CTN-0048 Cocaine Use Reduction with Buprenorphine (CURB) Walter Ling, M.D.
CTN NIDA-CTN-0046 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes T. John Winhusen, Ph.D., Eugene Somoza, M.D.
CTN NIDA-CTN-0044 Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders Edward V. Nunes, M.D.
CTN NIDA-CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Madhukar H. Trivedi, M.D.
CTN NIDA-CTN-AWARE Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. – an Adaptation of CTN-0032 Lisa Metsch, Ph.D., Grant Colfax, M.D.
CTN NIDA-CTN-0032 HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S. Lisa Metsch, Ph.D.
CTN NIDA-CTN-0031A An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers T. John Winhusen, Ph.D., Eugene Somoza, M.D.
CTN NIDA-CTN-0031 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement Dennis Donovan, Ph.D., Dennis Daley, Ph.D.
CTN NIDA-CTN-0030A3 Long-Term Follow-Up to CTN-0030 (A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence) Roger Weiss, M.D., Jennifer Sharpe Potter, Ph.D.
CTN NIDA-CTN-0030 A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence Walter Ling, M.D., Roger Weiss, M.D.
CTN NIDA-CTN-0029 A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD T. John Winhusen, Ph.D., Eugene Somoza, M.D.
CTN NIDA-CTN-0028 Osmotic-Release Methylphenidate (OROS-MPH) for ADHD in Adolescents with Substance Use Disorders Paula Riggs, M.D.
CTN NIDA-CTN-0027 Starting Treatment with Agonist Replacement Therapies (START) Walter Ling, M.D.
CTN NIDA-CTN-0021 Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse Kathleen Carroll, Ph.D., José Szapocznik, Ph.D.
CTN NIDA-CTN-0020 Job Seekers Training for Patients with Drug Dependence Dace Svikis, Ph.D.
CTN NIDA-CTN-0019 Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment Susan Tross, Ph.D.
CTN NIDA-CTN-0016 Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment Robert Forman, Ph.D.
CTN NIDA-CTN-0015 Women's Treatment for Trauma and Substance Use Disorders Denise Hien, Ph.D.
CTN NIDA-CTN-0014 Brief Strategic Family Therapy (BSFT) For Adolescent Drug Abusers José Szapocznik, Ph.D.
CTN NIDA-CTN-0013 Motivational Enhancement Therapy (MET) to Improve Treatment Utilization and Outcome in Pregnant Substance Users T. John Winhusen, Ph.D.
CTN NIDA-CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs Lawrence Brown, Jr., M.D., M.P.H.
CTN NIDA-CTN-0011 A Feasibility Study of a Telephone Enhancement Procedure (TELE) to Improve Participation in Continuing Care Activities Robert L. Hubbard, Ph.D., M.B.A.
CTN NIDA-CTN-0010 Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults George Woody, M.D.
CTN NIDA-CTN-0009 Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs Malcolm Reid, Ph.D.
CTN NIDA-CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation Dennis McCarty, Ph.D.
CTN NIDA-CTN-0007 Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics Maxine Stitzer, Ph.D.
CTN NIDA-CTN-0006 Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics Maxine Stitzer, Ph.D.
CTN NIDA-CTN-0005 MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Kathleen Carroll, Ph.D.
CTN NIDA-CTN-0004 MET to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Kathleen Carroll, Ph.D.
CTN NIDA-CTN-0003 Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Two Schedules Walter Ling, M.D.
CTN NIDA-CTN-0002 Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification Walter Ling, M.D.
CTN NIDA-CTN-0001 Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification Walter Ling, M.D.
DTMC NIDA-CSP-1026 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For Methamphetamine Dependence Ahmed Elkashef, M.D.
DTMC NIDA-CSP-1025 Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D.
DTMC NIDA-CSP-1018 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D.
DTMC NIDA-CSP-1008B A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Peter Bridge, M.D.
DTMC NIDA-CSP-1008A A Multicenter Efficacy/Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Peter Bridge, M.D., Paul J. Fudala, Ph.D.
DTMC NIDA-CSP-999 A Multicenter Clinical Trial of Buprenorphine in Treatment of Opiate Dependence Walter Ling, M.D., Donald R. Wesson, M.D., C. James Klett, Ph.D.
DTMC NIDA-CPU-0016 Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) Eugene Somoza, M.D.
Subscribe to No